Orion Nutraceuticals Inc. (CSE:ORI) subsidiary, Medic Oasis, has received construction permits from the City of Dorval to begin building its 31,000-square-foot cannabis production facility in Quebec.

Orion is a British Columbia based company that aims to become an ACMPR Licensed Producer through its 99% owned subsidiary Medic Oasis. Medic Oasis has submitted an application to become a licensed producer and sell medical marijuana under Health Canada’s Access to Cannabis for Medical Purposes Regulations.


In July 2018, Orion entered into an 11-year commercial lease agreement for 31,688 square feet of space in the City of Dorval, Quebec, for growing, manufacturing and distributing legal cannabis. Under the lease for the Dorval Property, Orion has a right of first offer on any adjacent space which becomes available for lease. If Orion does not obtain the necessary permits to cultivate legal cannabis, it has an option to terminate the lease after the first year.

“We are extremely excited to begin renovations on our future cannabis growing facility in Dorval, Quebec,” said Jonathan Fiteni, CEO of Orion Nutraceuticals. “The province of Quebec is home to over 20% of Canada’s population yet has less than 10% of Canada’s total LP’s. Orion views this as a tremendous advantage as the government of Quebec has stated it will endeavor to fulfill its cannabis needs with product grown within the borders of Quebec.”

Once approved, Orion anticipates that the Medic Oasis project will be operational by the third quarter of 2020.

About Orion Nutraceuticals Inc.

Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. Medic-Oasis, Orion’s subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 31,000 square foot facility expected by Q3 2020. Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Orion shares trade in Canada on the CSE under the symbol ORI.

Click here to connect with Orion Nutraceuticals Inc. (CSE:ORI) for an Investor Presentation. 

Source: www.stockwatch.com

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less